• 諮詢熱線 +852 3480 8393

Logo
繁中
EN
  • 首頁
  • 公司介紹
    • 背景
    • 免疫治療日本
    • 免疫治療香港
    • 專科醫生
  • 免疫細胞治療
    • 免疫細胞治療/自體免疫療法
    • 樹突狀細胞/DC疫苗療法
    • 淋巴因子活化殺傷細胞(殺手T細胞)療法
    • 自然殺傷細胞/NK細胞療法
    • 免疫治療成功率
    • 免疫治療副作用
    • 免疫治療費用
  • 醫生介紹
    • 日本
  • 最新資訊
  • 聯絡我們
  • 繁中
    • EN
首頁 > 最新資訊 > 臨床醫學報告 > Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses

Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses

  • Cell Mol Immunol
  • 2025-01-17
  • 1699 瀏覽

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264306/


Abstract

Dendritic cells are powerful antigen-presenting cells that are essential for the priming of T cell responses. In addition to providing T-cell-receptor ligands and co-stimulatory molecules for naive T cell activation and expansion, dendritic cells are thought to also provide signals for the differentiation of CD4+ T cells into effector T cell populations. The mechanisms by which dendritic cells are able to adapt and respond to the great variety of infectious stimuli they are confronted with, and prime an appropriate CD4+ T cell response, are only partly understood. It is known that in the steady-state dendritic cells are highly heterogenous both in phenotype and transcriptional profile, and that this variability is dependent on developmental lineage, maturation stage, and the tissue environment in which dendritic cells are located. Exposure to infectious agents interfaces with this pre-existing heterogeneity by providing ligands for pattern-recognition and toll-like receptors that are variably expressed on different dendritic cell subsets, and elicit production of cytokines and chemokines to support innate cell activation and drive T cell differentiation. Here we review current information on dendritic cell biology, their heterogeneity, and the properties of different dendritic cell subsets. We then consider the signals required for the development of different types of Th immune responses, and the cellular and molecular evidence implicating different subsets of dendritic cells in providing such signals. We outline how dendritic cell subsets tailor their response according to the infectious agent, and how such transcriptional plasticity enables them to drive different types of immune responses.

Source: Hilligan, Kerry L, and Franca Ronchese. “Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses.” Cellular & molecular immunology vol. 17,6 (2020): 587-599. doi:10.1038/s41423-020-0465-0


上一篇:Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment 下一篇:Dendritic Cell–Based Immunotherapy: State of the Art and Beyond

欄目分類

  • 新聞 18

最新文章

  • YouTube頻道「珍心活」訪問加藤洋一博士
    2025-08-03
  • 《健康旦》鄭丹瑞專訪林美君Connie | 在日本如何選擇醫生做進行疫細胞治療?
    2025-01-10
  • 香港演員陳先生陪同母親赴日治療感謝加藤洋一博士
    2024-07-03
  • 吉田家族捐贈1.2萬平方呎土地予加藤洋一醫生 | 日本法務大臣致賀
    2024-04-05
  • がんの先進医療 2025年1月第56期 | 先進醫療雜誌訪問加藤博士
    2025-04-02
  • 加藤博士的新建醫療大樓即將完工
    2024-01-19
  • 加藤醫生的專業團隊 | 科學家柳井博士的「奇幻實驗室」
    2023-11-10
  • 「人類的先天免疫力,遠勝於人力所研發的藥物」 – 免疫療法權威 加藤洋一
    2023-11-03
  • 日媒專訪名醫 | 日本晚期醫療現況
    2023-10-27
  • DC、LAK、NK三種免疫細胞療法的差異與選擇
    2023-10-19
  • 樹突狀細胞疫苗療法 | 加藤洋一醫生的免疫療法專業見解
    2023-08-09
  • 日本免疫細胞治療權威 | 加藤洋一博士
    2023-07-27
  • Natural Killer Cells in the Immune System: Your Body's First Line of Defense
    2025-10-13
  • Dendritic Cells Immune Response: The Commanders of Your Immune System
    2025-10-13
  • Dendritic Cells: Defining the Commanders of the Immune System and Their Role in Immunotherapy
    2025-10-13
  • Dendritic Cell Therapy Success Rate: An Evidence-Based Analysis
    2025-10-13
  • Dendritic Cell Therapy: An Advanced Cancer Treatment for Stage 4 Patients
    2025-10-13
所有文章
Logo
  • 電郵:info@asiaimmune.com
  • 電話/WhatsApp:+852 3480 8393
  • 微信:aicl_hk
  • 辦公時間:星期一至五 9:00am 至 6:00pm

免疫細胞治療

  • 免疫細胞治療/自體免疫療法
  • 樹突狀細胞/DC疫苗療法
  • 淋巴因子活化殺傷細胞(殺手T細胞)療法
  • 自然殺傷細胞/NK細胞療法
  • 免疫治療成功率
  • 免疫治療副作用
  • 免疫治療費用

公司地址

  • 香港中環皇后大道中36號興瑋大廈12樓1202室
    (📍Google Map)
  • +852 3480 8393

Copyright © 2026. Designed by Asia Immunotherapy Company Limited.